Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-6 of 6 for your search:
Drug:
ibritumomab tiuxetan
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Study of Two Associations of Rituximab and Chemotherapy, With a PET–Driven Strategy, in Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 59
Sponsor:
Other
Protocol IDs:
2007.462
, NCT00498043
2.
A Study of Zevalin and Simultaneous Application of BEAM High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
DSHNHL 2004-R4
, DSHNHL 2004-R4, NCT00521560
3.
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-Based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
CHUBX 2007/11
, NCT00607854
4.
Allogenic Stem Cell Transplantation (SCT) With Non-Myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
GELTAMO-Z-RIC-Allo
, EuDRACT nº:2007-003302-10, NCT00644371
5.
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
ZAR2007
, NCT00662948
6.
Phase I Study of a Conditioning Regimen Comprising High-Dose Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Vinorelbine Ditartrate- and Filgrastim (G-CSF)-Mobilized Autologous Stem Cell Transplantation in Elderly Patients With Relapsed or Refractory CD20-Positive Non-Hodgkin's Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
65 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
SWS-SAKK-37/05
, EU-20648, SPRI-SWS-SAKK-37/05, NCT00392691
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute